Storyline
FDA Commissioner Marty Makary, M.D., called J&J’s Tecvayli-Darzalex phase 3 showing the “most impressive second-line myeloma trial results in history.”
J&J's Tecvayli claims third national priority FDA approval Phil.Taylor Fri, 06/03/2026 - 10:59.
Evidence locked
Today's free sample is only available for the edition's flagship storyline.
Evidence preview
- FDA issues speedy approval to J&J’s Tecvayli-Darzalex comboBioPharma Dive
- FDA Commissioner Marty Makary, M.D., called J&J’s Tecvayli-Darzalex phase 3 showing the “most impressive second-line...Fierce Pharma (All)
- J&J's Tecvayli claims third national priority FDA approvalpharmaphorum